259 related articles for article (PubMed ID: 29764965)
1. Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study.
Tam LH; Shang Q; Li EK; Wong PC; Kwok KY; Kun EW; Yim IC; Lee VK; Yip RM; Pang SH; Lao VW; Mak QW; Cheng IT; Lau XS; Li TK; Zhu TY; Lee AP; Tam LS
J Rheumatol; 2018 Aug; 45(9):1229-1239. PubMed ID: 29764965
[TBL] [Abstract][Full Text] [Related]
2. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
3. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
[TBL] [Abstract][Full Text] [Related]
4. Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study.
Yue J; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Li M; Li TK; Mak WY; Zhu TY; Hung VW; Qin L; Tam LS
Semin Arthritis Rheum; 2018 Dec; 48(3):374-383. PubMed ID: 29858113
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with change in arterial stiffness in patients with rheumatoid arthritis: the JointHeart study.
Linde A; Gerdts E; Fevang BT; Eilertsen RK; Kringeland E; Alsing CL; Midtbø H
Blood Press; 2024 May; 33(1):2353167. PubMed ID: 38824646
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.
Tam LS; Shang Q; Li EK; Wong S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
Semin Arthritis Rheum; 2013 Feb; 42(4):333-45. PubMed ID: 22920235
[TBL] [Abstract][Full Text] [Related]
7. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
[TBL] [Abstract][Full Text] [Related]
8. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
9. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
11. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
12. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
Emery P; Tanaka Y; Bykerk VP; Bingham CO; Huizinga TWJ; Citera G; Huang KG; Wu C; Connolly SE; Elbez Y; Wong R; Lozenski K; Fleischmann R
Arthritis Res Ther; 2023 Apr; 25(1):67. PubMed ID: 37087459
[TBL] [Abstract][Full Text] [Related]
13. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
14. Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.
Curtis JR; Emery P; Karis E; Haraoui B; Bykerk V; Yen PK; Kricorian G; Chung JB
Arthritis Rheumatol; 2021 May; 73(5):759-768. PubMed ID: 33205906
[TBL] [Abstract][Full Text] [Related]
15. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.
Paulshus Sundlisæter N; Olsen IC; Aga AB; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
Rheumatology (Oxford); 2018 Nov; 57(11):2022-2031. PubMed ID: 30053199
[TBL] [Abstract][Full Text] [Related]
16. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
17. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
18. The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study.
O'Connor A; Thorne C; Kang H; Tin D; Pope JE
BMC Musculoskelet Disord; 2016 Aug; 17(1):364. PubMed ID: 27558249
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
20. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
